Baumann Cosmetic & Research Institute Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2010
NCT01186068
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Baumann Cosmetic and Research Institute

Active Ingredients

Drugs in Phase 3 Trials (1)

brimonidine (alphagan) (1 trial)

Drugs in Phase 2 Trials (1)

oxymetazoline (ocuclear) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Erythema (Phase 3)

Rosacea (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2